雾化器的进步用于加压腹腔内气溶化疗 (PIPAC)
Xiaosong Lin1,2, Zifeng Yang2, Yong Li2
1Department of Gastrointestinal Surgery, Jieyang People's Hospital, Jieyang, China.
Pleura and peritoneum
|December 18, 2025
概括
压缩性腹腔内喷雾剂化疗 (PIPAC) 增强了腹腔内转移的药物输送. 研究重点是优化雾化器技术,以改善治疗结果,并探索新的气溶装置.
科学领域:
- 在瘤学瘤学.
- 药物输送系统 药物输送系统
- 医疗工程 医学工程
背景情况:
- 压缩性腹腔内喷雾剂化疗 (PIPAC) 是一种向腹腔腔提供化疗的创新方法.
- 临床证据表明PIPAC在治疗腹转移时的安全性和有效性.
- 优化雾化器技术对于提高PIPAC治疗结果至关重要.
研究的目的:
- 综合审查PIPAC雾化器开发的全球进展.
- 检查PIPAC的替代气溶装置和评估方法.
- 确定PIPAC中新型雾化器应用的未来研究方向.
主要方法:
- 对PIPAC雾化器开发和替代设备的全球研究进行审查.
- 分析当前评估参数和雾化器性能方法的分析.
- 探索PIPAC技术中的新兴趋势和未来研究途径.
主要成果:
- 在改进PIPAC雾化器设计方面取得了重大进展.
- 已经开发出了几种具有明显特征的临床适用雾化器.
- 雾化器评估方法的持续改进和与其他模式的整合显示出有希望.
结论:
- 在雾化器技术的持续创新对于推进PIPAC至关重要.
- 对新型雾化剂和评估技术的进一步研究将提高治疗疗效.
- 将PIPAC与其他物理模式集成为改善治疗结果提供了潜力.
相关概念视频
Inhaled Medications
687
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
687
Mechanical Ventilation III: Noninvasive Ventilation
480
Noninvasive positive-pressure ventilation (NIPPV), continuous positive airway pressure (CPAP), and bilevel positive airway pressure (BiPAP) are essential methods in respiratory care. These ventilation techniques offer unique benefits for patients with various respiratory conditions, providing adequate support without requiring intubation. Let's explore how each method is crucial in improving patient outcomes and enhancing respiratory therapy.
Noninvasive Positive-Pressure Ventilation...
Noninvasive Positive-Pressure Ventilation...
480
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
436
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
436


